1 / 41

Efficacy of Bispecific Cytotoxin DTEGFATF in Treating Human Glioblastoma Tumors

This research by Travis Spangler (2008-2009) investigates the potential effectiveness of the bispecific cytotoxin DTEGFATF in targeting and ameliorating glioblastoma tumors in humans. The study outlines previous findings and methodologies, examines receptor interactions and cell lines including U-87 and HUVEC, and discusses proliferation assays and blocking assays to measure the toxicity and efficacy of DTEGFATF. The implications of the research contribute to future clinical trials and advancements in cancer treatment. Acknowledgments go to Dr. Daniel Vallera and the University of Minnesota.

tamera
Download Presentation

Efficacy of Bispecific Cytotoxin DTEGFATF in Treating Human Glioblastoma Tumors

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Effectiveness of Bispecific Cytotoxin (DTEGFATF) in Ameliorating Human Glioblastoma Tumors Travis Spangler 2008-2009

  2. Research Problem http://upload.wikimedia.org/wikipedia/commons/c/c0/Glioblastoma_-_MR_sagittal_with_contrast.jpg

  3. Background: Stish et al. (2007) DTEGF13 Diphtheria toxin epidermal growth factor 13

  4. DTEGF13 DTIL13 DTEGF IL13 Diphtheria toxin epidermal growth factor Diphtheria toxin amino acid transfer

  5. Background: Stish et al. (2007) DTEGF13 Diphtheria toxin epidermal growth factor 13

  6. DTEGFATF ATF Diphtheria toxin epidermal growth factor amino terminal fragment

  7. DTEGFATF ATF DTAT DTEGF ATF Diphtheria toxin amino acid transfer Diphtheria toxin epidermal growth factor

  8. Background: Stish et al. (2008) DTEGF

  9. Background: Stish et al. (2008) • DTEGF

  10. Background: Vallera et al. (2002) • DTAT

  11. Background: Vallera et al. (2002) • DTAT

  12. http://www.biooncology.com/bioonc/images/her-main.jpg

  13. Receptor Receptor Receptor Receptor Receptor Receptor Receptor Receptor Receptor Receptor http://www.biooncology.com/bioonc/images/her-main.jpg

  14. DTEGFATF • DTEGF • DTAT

  15. DTEGFATF • DTEGF • DTAT • DTEGF + DTAT

  16. Cell Lines U-87 HUVEC HPB-MLT http://www.assaysoft.com/gallery/02Microscopy/MicroscopyGallery/12/Human%20Umbilical%20Vein%20Endothelial%20Cells%20(HUVEC).jpg http://www.hpb.org.uk/userimages/panfigure2.jpg http://data-integrator.com

  17. Cell Lines U-87 HUVEC HPB-MLT http://www.assaysoft.com/gallery/02Microscopy/MicroscopyGallery/12/Human%20Umbilical%20Vein%20Endothelial%20Cells%20(HUVEC).jpg http://www.hpb.org.uk/userimages/panfigure2.jpg http://data-integrator.com

  18. Cell Lines U-87 HUVEC HPB-MLT http://www.assaysoft.com/gallery/02Microscopy/MicroscopyGallery/12/Human%20Umbilical%20Vein%20Endothelial%20Cells%20(HUVEC).jpg http://www.hpb.org.uk/userimages/panfigure2.jpg http://data-integrator.com

  19. Cell Lines U-87 HUVEC HPB-MLT http://www.assaysoft.com/gallery/02Microscopy/MicroscopyGallery/12/Human%20Umbilical%20Vein%20Endothelial%20Cells%20(HUVEC).jpg http://www.hpb.org.uk/userimages/panfigure2.jpg http://data-integrator.com

  20. Proliferation Assays

  21. Proliferation Assays

  22. Proliferation Assays

  23. Proliferation Assays

  24. Proliferation Assays

  25. Proliferation Assay Results

  26. Proliferation Assay Results

  27. Proliferation Assay Results

  28. Proliferation Assay Results

  29. Proliferation Assay Results

  30. Proliferation Assay Results

  31. Proliferation Assay Results

  32. Blocking Assay http://www.biooncology.com/bioonc/images/her-main.jpg

  33. Blocking Assay http://www.biooncology.com/bioonc/images/her-main.jpg

  34. Blocking Assay DTEGFATF DTEGFATF DTEGFATF DTEGFATF DTEGFATF DTEGFATF DTEGFATF DTEGFATF DTEGFATF DTEGFATF http://www.biooncology.com/bioonc/images/her-main.jpg

  35. Blocking Assay http://www.biooncology.com/bioonc/images/her-main.jpg

  36. Blocking Assay Results

  37. Blocking Assay Results

  38. Limitations • Blocking assay • Bispecific cytotoxin disperses throughout tumors • Concentration of antibodies

  39. Future Work • Clinical trial

  40. Acknowledgements • Dr. Daniel Vallera • The University of Minnesota • Vallera Lab • Lois Fruen • Advanced Science Research

  41. Effectiveness of Bispecific Cytotoxin (DTEGFATF) in Ameliorating Human Glioblastoma Tumors Travis Spangler 2008-2009

More Related